Histopathology 49 , 358364
Clinical studies have shown that tirzepatide: Significantly reduces hemoglobin A1C levels compared to placebo Promotes weight loss in a dose-dependent manner May have potential benefits for non-alcoholic fatty liver disease (NAFLD) patients Tirzepatide is typically administered as follows: Once-weekly subcutaneous injection Available in various strengths (e.g., 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) Dose is usually titrated over time to reach the target dose Common side effects may include: Nausea Diarrhea Decreased appetite Vomiting Constipation Abdominal pain Tirzepatide should be used with caution in patients with: History of pancreatitis Severe gastrointestinal disease Diabetic retinopathy Pregnancy: Tirzepatide should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus
One such peptide gaining attention is BPC-157 (Body Protection Compound-157) , studied for its anti-inflammatory, tissue-repair, and healing-support properties
When our team performs a comprehensive body analysis, we evaluate more than just your weight
Kindly contact the FDA Center for Food Regulation and Research through e-mail at [email protected] , or call (02) 857-1900 loc
.png&w=828&q=100)
